Editas Medicine (EDIT) Gets a Sell From Bank of America Securities
H.C. Wainwright Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $3
Editas Medicine Analyst Ratings
HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target
JonesTrading Maintains Editas Medicine(EDIT.US) With Hold Rating
Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Maintains Target Price $1
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $1 to $5
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Editas Medicine (EDIT) Gets a Buy From Evercore ISI
Analysts' Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4
Editas Medicine: Balancing Financial Stability and Strategic Uncertainties With a Hold Rating
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Barclays Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $3
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $3
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Announces Target Price $1
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $3
TD Cowen Maintains Editas Medicine(EDIT.US) With Buy Rating